Oligo Medic
Was founded in 2010 by pioneers of chitosan as a material for biomedical applications, with over 25 years of experience developing medical devices.
Their earlier efforts culminated in the commercialization of BST-CarGel, a cartilage repair product acquired by Smith&Nephew.
Initially focused on its novel technology platform, Oligo Medic has developed a fully self-gelling injectable scaffold for cartilage repair. The company rapidly reached commercialization milestones for its first product JointRep including CE mark in 2014.
By 2021 there had been over 7000 patients treated in over 20 countries spanning Canada, Europe, Australia/New Zealand, Southeast Asia and Latin America. Growth potential for the JointRep platform includes use of JointRep for other body joints than the knee, and use of JointRep as a carrier for biologics (PRP, stem cells, etc.).
Oligo Medic operates under a Quality Management System compliant with the requirements of ISO13485:2016.
Submitted package to FDA in May to initiate JointRep® trial in the United States
2020
Obtained license from TGA for JointRep® in Australia.
2019
Obtained license from Health Canada for JointRep®.
2018
Gaining market penetration in Europe, ANZ regions, South East Asia, and Latin America
2018
Preliminary steps taken toward procedures with FDA for market approval in the US.
2018
Very favorable results on clinical trial published in Journal of Clinical Orthopedics and Trauma.
2018
Initiated European controlled clinical trial comparing microfracture to microfracture + JointRep®.
2015
Initial experimentation with JointRep® and microfracture. Results are highly favorable with fast pain relief, accelerated recovery time, and nice cartilage regrowth.
2014
Obtained CE mark in October. Structured OligoMedic for distribution partnership and initiated case studies and post market evaluation.
2013
Follow up case series on Health Canada SAP.
2011
Creation of Oligo Medic Inc. Development of technology platform. Bench testing and pre-clinical characterization. Initiated Health Canada Special Access Program ("SAP"). Successful first-in-man JointRep® operation.
2010
Creation of Oligo Medic Inc. Development of technology platform. Bench testing and pre-clinical characterization. Initiated Health Canada Special Access Program ("SAP"). Successful first-in-man JointRep® operation.
2010
Manufacturing, packaging, and shipping processes defined.
2012
Creation of Oligo Medic Inc. Development of technology platform. Bench testing and pre-clinical characterization. Initiated Health Canada Special Access Program ("SAP"). Successful first-in-man JointRep® operation.
2010
Creation of Oligo Medic Inc. Development of technology platform. Bench testing and pre-clinical characterization. Initiated Health Canada Special Access Program ("SAP"). Successful first-in-man JointRep® operation.
2010
Timeline
Initiating large-scale JointRep® RCT study in Australia, New Zealand & Canada to demonstrate quantitative MRI evidence of superiority of cartilage repair tissue, supporting existing clinical findings & outlook for long-term clinical outcomes.
2021
Obtained license from TGA for JointRep® in Australia.
2019
Gaining market penetration in Europe, ANZ regions, South East Asia, and Latin America
2018
Initiated European controlled clinical trial comparing microfracture to microfracture + JointRep®.
2015
Obtained CE mark in October. Structured OligoMedic for distribution partnership and initiated case studies and post market evaluation.
2013
Follow up case series on Health Canada SAP.
2011
BST-CarGel gets CE mark
2012
Development of BST-CarGel begins: multiple pre-clinical publications
2000
BST-Gel discovered & patented: first polysaccharide-based thermogel
1998
BioSynTech founded by Dr. Amine Selmani. (BSY was founded as a spin-off from Ecole Polytechnique de Montréal).
Product concepts defined in three new categories: chronic wounds, ophthalmology & spine. Development gracefully supported by MEI, MEDTEQ+ & NSERC.
2021
Obtained license from Health Canada for JointRep®.
2018
Very favorable results on clinical trial published in Journal of Clinical Orthopedics and Trauma.
2018
Initial experimentation with JointRep® and microfracture. Results are highly favorable with fast pain relief, accelerated recovery time, and nice cartilage regrowth.
2014
Manufacturing, packaging, and shipping processes defined.
2012
Creation of Oligo Medic Inc. Development of technology platform. Bench testing and pre-clinical characterization. Initiated Health Canada Special Access Program ("SAP"). Successful first-in-man JointRep® operation.
2010
BST-CarGel clinical trial begins
2004
Seminal BST-Gel publication in Biomaterials: 1000+ citations to date
2000
The "World's first " discovery of the gelling properties of the Chitosan buffered solution at Ecole Polytechnique de Montréal.
1995
1995